Background: We analyzed 2017 healthcare facility-onset (HO) vancomycin-resistant (VRE) bacteremia data to identify hospital-level factors that were significant predictors of HO-VRE using the Centers for Disease Control and Prevention (CDC) National Healthcare Safety Network (NHSN) multidrug-resistant organism and reporting module. A risk-adjusted model that can be used to calculate the number of predicted HO-VRE bacteremia events in a facility was developed, thus enabling the calculation of VRE standardized infection ratios (SIRs).
Methods: Acute-care hospitals reporting at least 1 month of 2017 VRE bacteremia data were included in the analysis. Various hospital-level characteristics were assessed to develop a best-fit model and subsequently derive the 2018 national and state SIRs.
Results: In 2017, 470 facilities in 35 states participated in VRE bacteremia surveillance. Inpatient VRE community-onset prevalence rate, average length of patient stay, outpatient VRE community-onset prevalence rate, and presence of an oncology unit were all significantly associated (all 95% likelihood ratio confidence limits excluded the nominal value of zero) with HO-VRE bacteremia. The 2018 national SIR was 1.01 (95% CI, 0.93-1.09) with 577 HO bacteremia events reported.
Conclusion: The creation of an SIR enables national-, state-, and facility-level monitoring of VRE bacteremia while controlling for individual hospital-level factors. Hospitals can compare their VRE burden to a national benchmark to help them determine the effectiveness of infection prevention efforts over time.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8642455 | PMC |
| http://dx.doi.org/10.1017/ice.2021.215 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Antimicrobial Resistance Profile of Enterococcal Isolates From Clinical Specimens at a Tertiary Care Hospital in Western Maharashtra, India.
Cureus
November 2024
Department of Microbiology, Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth (Deemed to Be University), Karad, IND.
Background , once benign intestinal flora, has transformed into formidable nosocomial pathogens as a result of the accelerated emergence of antibiotic resistance represents a major global health challenge, particularly within hospital settings. has grown more prevalent in nosocomial infections, such as urinary tract infections (UTIs), surgical site infections (SSIs) and bacteremia. The potential emergence of vancomycin-resistant (VRE) strains further complicates treatment choices for multi-drug resistant (MDR) infections.
View Article and Find Full Text PDFRectal colonization with multidrug-resistant organisms and risk for bloodstream infection among high-risk Greek patients.
Eur J Clin Microbiol Infect Dis
November 2024
Laboratory of Clinical Microbiology, School of Medicine, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Background: Studies link multidrug-resistant organism (MDRO) rectal colonization to increased infection risk, data from Greece, a country with high rates of MDRO, are limited.
Methods: We assessed bloodstream infection (BSI) risk following rectal colonization by MDROs across three Greek hospitals (2019-2022).
Results: Of 4,370 inpatients, 31.
Management of Recurrent Vancomycin-resistant Bacteremia With Oritavancin: A Case Report.
In Vivo
October 2024
Department of Internal and Hospital Medicine, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, U.S.A.
Background/aim: Vancomycin-resistant Enterococcus causes significant morbidity, mortality, and excess healthcare costs when compared to vancomycin-susceptible isolates. Patients with hematological malignancies, especially those who undergo hematopoietic stem cell transplantation, are at a particularly high risk for infections with vancomycin-resistant Enterococcus, with mortality ranging from 40-100%. Linezolid and daptomycin are the two most commonly used antibiotics for treatment of vancomycin-resistant enterococcal infections, however, there has been recent emergence of resistance to these drugs as well.
View Article and Find Full Text PDFGlobal landscape of vancomycin-resistant enterococci in hematopoietic stem-cell transplantation patients: a systematic review and meta-analysis.
BMC Infect Dis
October 2024
Infectious Diseases Research Center, AJA University of Medical Sciences, Tehran, Iran.
Background: One of the main risks of infection after hematopoietic stem cell transplantation (HSCT) is infection by gram-positive bacteria, including vancomycin-resistant enterococci (VRE). Based on the format of a global review and meta-analysis study, this study aims to investigate the incidence of VRE bloodstream infection (BSI) after HSCT in colonized individuals.
Methods: The keywords of the systematic search included vancomycin-resistant enterococci and HSCT.
Carbapenem-resistant Citrobacter amalonaticus and VRE bacteraemia in an immunocompetent patient after a urological Rezum procedure.
Access Microbiol
October 2024
Department of Medicine, Division of Infectious Diseases, University of Tennessee Health Science Center, Memphis, TN, USA.
Article Synopsis
- A 62-year-old man experienced severe symptoms, including blood in urine, fever, and chills, just a day after a Rezum procedure.
- He was diagnosed with bacteraemia caused by bacteria resistant to carbapenems and vancomycin.
- The patient successfully received treatment with drugs like daptomycin and eravacycline, highlighting the limited information available on such infections.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!